CAMBRIDGE, Mass. and WESTMINSTER, Colo., May 12, 2021 /PRNewswire/ -- Leap Therapeutics (Nasdaq: LPTX), a biotechnology company focused on developing targeted and immuno-oncology therapeutics, and ...
MINNEAPOLIS, July 11, 2019 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ:TECH) today announced the expansion of the Advanced Cell Diagnosticsâ„¢-branded RNAscope platform with release of the RNAscope ...
Bio-Techne has added new capabilities and options to its Advanced Cell Diagnostics (ACD)-branded RNAscope® and BaseScopeâ„¢ in situ hybridization (ISH) Assay Services Portfolio to improve biotech and ...
An integrated assay using proprietary RNAscopeâ„¢ and miRNAscopeâ„¢ technologies to measure the biodistribution and function of novel gene therapies and endogenous regulatory RNAs. Small regulatory RNAs, ...
In this webinar we will provide an overview of RNAscopeâ„¢ ISH technology, then discuss our new RNAscope multiomic applications coming soon. RNAscope is the gold standard for RNA ISH -providing ...
MINNEAPOLIS, Sept. 22, 2020 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ:TECH) today announced the expansion of the Advanced Cell Diagnostics (ACD)-branded RNAscopeâ„¢ technology with release of the ...
SEATTLE & MINNEAPOLIS--(BUSINESS WIRE)--NanoString Technologies, Inc. (NASDAQ:NSTG), a leading provider of life science tools for discovery and translational research, and Bio-Techne (NASDAQ:TECH), a ...
Advanced Cell Diagnostics (ACD), a Bio-Techne (TECH) spatial biology brand, achieves technical breakthrough enabling protease-free, same-slide detection of protein and RNA biomarkers using ...
Leica Biosystems, a Danaher company and a global leader in anatomic pathology solutions, and Bio-Techne (NASDAQ: TECH), a global provider of life science tools, reagents and diagnostic products, ...
This webinar will provide an overview of the Bio-Techne technologies being used by Biopharma for the development of biomarkers and companion diagnostic assays to support their therapeutic programs, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results